Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Shenzhen Bay Laboratory has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is assigned to 1 examiner and 1 art unit, so prosecution is concentrated in a single examination path.
MEAH, MOHAMMAD Y is the busiest examiner, with 1 pending office action. Counsel can focus preparation on the issues identified in that record and the practice of the assigned art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MEAH, MOHAMMAD Y | 1 | 70.7% | +42.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18899715 | E. COLI EXPRESSED RECOMBINANT HUMAN MICROPLASMIN, A PRODUCTION METHOD THEREOF, A PHARMACEUTICAL COMPOSITION AND A KIT COMPRISING THEREOF, A METHOD AND AN APPLICATION OF TREATING THROMBOEMBOLISM RELATED DISEASES BY USING THEREOF | MEAH, MOHAMMAD Y | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18899715 | E. COLI EXPRESSED RECOMBINANT HUMAN MICROPLASMIN, A PRODUCTION METHOD THEREOF, A PHARMACEUTICAL COMPOSITION AND A KIT COMPRISING THEREOF, A METHOD AND AN APPLICATION OF TREATING THROMBOEMBOLISM RELATED DISEASES BY USING THEREOF | MEAH, MOHAMMAD Y | — |
| Art Unit | Apps |
|---|---|
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18899715 | E. COLI EXPRESSED RECOMBINANT HUMAN MICROPLASMIN, A PRODUCTION METHOD THEREOF, A PHARMACEUTICAL COMPOSITION AND A KIT COMPRISING THEREOF, A METHOD AND AN APPLICATION OF TREATING THROMBOEMBOLISM RELATED DISEASES BY USING THEREOF | MEAH, MOHAMMAD Y | 1652 | §103§112Other | Non-Final OA | — | Pending | Sep 27, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShenzhen Bay Laboratory has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Mohammad Y Meah has the most, with 1 of Shenzhen Bay Laboratory's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
